Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RBOT.WS vs ALGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ALGN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

ALGN Overall Winner 6-Pillar Tally: RBOT.WS 0 – 6 ALGN Matrix Metrics: RBOT.WS 1 – 9 ALGN

As of Nov 20, 2026, Align Technology Inc (ALGN) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas ALGN carries 40.4/100 (SELL) at $155.17 (12.6x Forward P/E, 19.6% operating margin).

  • Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ALGN 40.4/100 SELL), ALGN captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (19.6% vs. N/A operating margin) and revenue trajectory (+1.9% vs. N/A YoY).
  • Technical & Structure Timing Caution: RBOT.WS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ALGN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RBOT.WS vs ALGN
RBOT.WS NYSE
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.01
-24.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
50.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
ALGN NASDAQ Head-to-Head Winner
Align Technology Inc
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$155.17
-2.82% 1D
Market Cap $11.3B
TTM Revenue $4.16B
Forward P/E 12.6x
Beta / 30D Vol 1.15β · 46% Vol
Unified Composite Score
40.4 / 100 SELL
Tech 20.0 Fund 47.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope 0.3%) with fading momentum, RSI 45
RSI-14: 44.8 · SMA20: $161.08 · SMA50: $152.50

6-Pillar Scorecard Institutional Category Breakdown (RBOT.WS 0 – 6 ALGN)

Columns: Metric · RBOT.WS · ALGN
1. Valuation Multiples ALGN
Forward P/E N/M 12.6x
Trailing P/E N/M 23.3x
PEG Ratio N/M 0.75x
EV / Revenue N/M 2.5x
2. Growth & Scale ALGN
Revenue Growth (YoY) N/A +1.9%
Earnings Growth (YoY) N/A +143.6%
TTM Revenue (USD) N/A $4.16B
Market Cap N/A $11.3B
3. Profitability & Quality ALGN
Gross Margin N/A 71.5%
Operating Margin N/A 19.6%
Net Profit Margin N/A 11.8%
Return on Equity (ROE) N/A 11.9%
4. Balance Sheet & Cash Flow ALGN
Cash Generation (TTM) N/A $602M
Cash Flow Margin N/A 14.5%
Net Cash / Leverage N/A ROE $998M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ALGN
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 31.9% (10th %ile)
Put/Call OI Skew N/A 0.83x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat ALGN
OpEx & R&D Intensity N/A 51.9% of Rev ($2.16B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RBOT.WS (1) vs ALGN (9)
Institutional Metric RBOT.WS ALGN Criterion Row Edge
Market Capitalization
Scale
N/A $11.3B Larger Scale ALGN
Trailing P/E Ratio
Valuation
N/M 23.3x Lower Multiple ALGN
Forward P/E Ratio
Valuation
N/M 12.6x Lower Multiple ALGN
Revenue Growth (YoY)
Growth
N/A +1.9% Higher Growth ALGN
Operating Margin (TTM)
Profitability
N/A 19.6% Higher Margin ALGN
Net Profit Margin
Profitability
N/A 11.8% Higher Margin ALGN
Return on Equity (ROE)
Capital Efficiency
N/A 11.9% Higher ROE ALGN
52-Week Range Position
Momentum
0% ($0–$0) 34% ($132–$200) Stronger Trend ALGN
Beta / 30D Volatility
Risk Regime
N/A 1.15β · 46% Vol Lower Realized Risk ALGN
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 40.4 / 100 (SELL) Higher Composite RBOT.WS
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.16B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 71.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.75x PEG · 2.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $602M ($998M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ALGN +89.69 pp
RBOT.WS: -67.2% · ALGN: +22.49%
3M Horizon ALGN +89.69 pp
RBOT.WS: -67.2% · ALGN: +22.49%
6M Horizon ALGN +89.69 pp
RBOT.WS: -67.2% · ALGN: +22.49%
1Y Horizon ALGN +89.69 pp
RBOT.WS: -67.2% · ALGN: +22.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RBOT.WS vs ALGN. Trailing 12-month operating profitability (RBOT.WS N/A vs ALGN 19.6%) and valuation multiples (RBOT.WS N/M vs ALGN 12.6x Forward P/E) are benchmarked directly in Pillar 4 below.

RBOT.WS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ALGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.16B
Gross Margin71.5%
Op. Margin19.6%
ROE / Fwd P/E11.9% · 12.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RBOT.WS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RBOT.WS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ALGN SURGE
9d in phase · OBV DISTRIBUTION
Current IV 31.9%
IV Percentile 10th %ile
Put/Call OI Skew 0.83x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ALGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $165.98 · IV 40.3%

ALGN Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($16,598)

Compare $16,598 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 40.3% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $165 / $180 Bull Call Spread

Buy 1x $165C · Sell 1x $180C · 31d

Net Entry $399 Debit
T+5d @ +5% Move +$234 (+59%)
Max Risk / Buffer $399 Capped
5d Edge & Liquidity 1.1x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $150 / $140 Bull Put Spread

Sell 1x $150P · Buy 1x $140P · 31d

Net Entry $99 Credit
Max Credit / Yield +$99 (+11.0% RoM)
Max Risk / Buffer -10.2% Cushion ($901 Mgn)
5d Edge & Liquidity 83% PoP · Liq B
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq B

Dec 18 $155P / $165-$180C Seagull

Sell 1x $155P · Buy 1x $165/$180C · 31d

Net Entry $196 Debit
T+5d @ +5% Move +$383 (+14.6% RoM)
Max Risk / Buffer -6.6% Put Cushion ($2,621 Mgn)
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RBOT.WS Moat Profile Cyclical / Execution-Driven Positioning
Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ALGN Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.3B market capitalization and 19.6% operating margin.
OpEx & R&D Reinvestment 51.9% of Rev ($2.16B)
90D Engineering Disclosures 0 Published

Investor FAQ RBOT.WS vs ALGN Key Questions & Quantitative Answers

As of Nov 20, 2026, Align Technology Inc (ALGN) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas ALGN carries 40.4/100 (SELL) at $155.17 (12.6x Forward P/E, 19.6% operating margin). Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ALGN 40.4/100 SELL), ALGN captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (19.6% vs. N/A operating margin) and revenue trajectory (+1.9% vs. N/A YoY). Technical & Structure Timing Caution: RBOT.WS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ALGN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ALGN leads the Growth & Scale pillar: RBOT.WS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ALGN at +1.9% YoY revenue growth and +143.6% YoY earnings growth on $4.16B TTM revenue (71.5% gross margin, 19.6% operating margin). On trailing 12-month operating scale, RBOT.WS generates N/A in USD-normalized revenue versus $4.16B for ALGN. In operating R&D and SG&A reinvestment, RBOT.WS deploys N/A (0 90-day corporate R&D disclosures) versus 51.9% of Rev ($2.16B) (0 disclosures) for ALGN.

ALGN screens cheaper on headline valuation multiples. RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ALGN trades at 12.6x Forward P/E, 23.3x Trailing P/E, 0.75x PEG, and 2.5x EV/Revenue (14.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RBOT.WS (N/A ROE) versus ALGN (11.9% ROE) capital efficiency.

In options market volatility and institutional positioning, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, ALGN carries 31.9% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.83x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (1.15β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.